Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OptiNose, Inc.
The latest drug development news and highlights from our US FDA Performance Tracker.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.
- Medical Devices
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- OptiNose AS
- OptiNose UK Ltd.
- OptiNose US, Inc.